131TiP A phase I–III platform study evaluating the safety and efficacy of multiple therapies in patients (pts) with biomarker-defined locally advanced, unresectable stage III non-small cell lung cancer (NSCLC)

MLA

L. Paz-Ares, et al. “131TiP A Phase I–III Platform Study Evaluating the Safety and Efficacy of Multiple Therapies in Patients (Pts) with Biomarker-Defined Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC).” Journal of Thoracic Oncology, vol. 18, Apr. 2023, p. S114. EBSCOhost, https://doi.org/10.1016/s1556-0864(23)00386-6.

APA

L. Paz-Ares, C.M. Gay, C. Zhou, T. Kato, L. Corrales, K. Redhead, A. Rahman, D. Bradley, E. Theogaraj, K.E. Hutchinson, S.M. Shagan, & B.J. Solomon. (2023). 131TiP A phase I–III platform study evaluating the safety and efficacy of multiple therapies in patients (pts) with biomarker-defined locally advanced, unresectable stage III non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology, 18, S114. https://doi.org/10.1016/s1556-0864(23)00386-6

Chicago

L. Paz-Ares, C.M. Gay, C. Zhou, T. Kato, L. Corrales, K. Redhead, A. Rahman, et al. 2023. “131TiP A Phase I–III Platform Study Evaluating the Safety and Efficacy of Multiple Therapies in Patients (Pts) with Biomarker-Defined Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC).” Journal of Thoracic Oncology 18 (April): S114. doi:10.1016/s1556-0864(23)00386-6.